149 related articles for article (PubMed ID: 33740337)
1. Prognostic factors for incomplete response in thyroid microcarcinoma: an analysis of initial response to therapy in 517 patients.
Faro FN; Simões VRF; Ricardo GP; Cabral CP; de Cássia Braga Ribeiro K; Scalissi NM; Cury AN; Marone MM; do Prado Padovani R; Ferraz C
Arch Endocrinol Metab; 2021 Oct; 65(5):579-587. PubMed ID: 33740337
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-risk thyroid carcinoma: indicators of a poor prognosis.
Faro FN; Bezerra ÂMLB; Scalissi NM; Cury AN; Marone MM; Ferraz C; do Prado Padovani R
Arch Endocrinol Metab; 2021 May; 64(6):764-771. PubMed ID: 34033287
[TBL] [Abstract][Full Text] [Related]
3. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
4. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality.
Chow SM; Law SC; Chan JK; Au SK; Yau S; Lau WH
Cancer; 2003 Jul; 98(1):31-40. PubMed ID: 12833452
[TBL] [Abstract][Full Text] [Related]
5. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
[TBL] [Abstract][Full Text] [Related]
6. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients.
Mercante G; Frasoldati A; Pedroni C; Formisano D; Renna L; Piana S; Gardini G; Valcavi R; Barbieri V
Thyroid; 2009 Jul; 19(7):707-16. PubMed ID: 19348581
[TBL] [Abstract][Full Text] [Related]
8. [Draft of the best medical treatment in patients with low-risk thyroid cancer].
Vlček P; Nováková D; Vejvalka J; Zimák J; Křenek M; Vošmiková K; Smutný S; Bavor P; Astl J; Lukáš J
Vnitr Lek; 2015 Sep; 61(9):769-77. PubMed ID: 26465275
[TBL] [Abstract][Full Text] [Related]
9. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969
[TBL] [Abstract][Full Text] [Related]
10. Does total tumour diameter, multifocality, number of tumour foci, or laterality predict lymph node metastasis or recurrence in differentiated thyroid cancer?
Elbasan O; Ilgın C; Gogas Yavuz D
Endokrynol Pol; 2023; 74(2):153-167. PubMed ID: 37039491
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected].
Al-Qahtani KH; Al Asiri M; Tunio MA; Aljohani NJ; Bayoumi Y; Fatani H; AlHadab A
J Otolaryngol Head Neck Surg; 2015 Dec; 44():51. PubMed ID: 26621255
[TBL] [Abstract][Full Text] [Related]
12. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
13. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
[No Abstract] [Full Text] [Related]
17. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.
Mendoza ES; Lopez AA; Valdez VA; Cunanan EC; Matawaran BJ; Kho SA; Sero-Gomez MH
J Endocrinol Invest; 2016 Jan; 39(1):55-62. PubMed ID: 26036600
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
[TBL] [Abstract][Full Text] [Related]
19. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.
Chow SM; Yau S; Kwan CK; Poon PC; Law SC
Endocr Relat Cancer; 2006 Dec; 13(4):1159-72. PubMed ID: 17158761
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for nodal recurrence in differentiated thyroid cancers.
Kaur J; Nadarajan A; Janardhan D; George NA; Thomas S; Varghese BT; Krishna J
Cancer Treat Res Commun; 2023; 36():100728. PubMed ID: 37336036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
